The Long-Term Effect of Eicosapentaenoic Acid on Serum Levels of Lipoprotein (a) and Lipids in Patients with Vascular Disease

The effects of eicosapentaenoic acid (EPA) on serum lipoprotein (a) (Lp (a)) and other lipid levels in patients with vascular disease were examined. The serum levels of Lp (a), total cholesterol (TC), triglyceride (TG), low-density lipoprotein (LDL) and very-low-density lipoprotein (VLDL) were measu...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Atherosclerosis and Thrombosis 1996, Vol.2(2), pp.107-109
Main Authors: Shinozaki, Koji, Kambayashi, Jun-ichi, Kawasaki, Tomio, Uemura, Yoshio, Sakon, Masato, Shiba, Eiichi, Shibuya, Takashi, Nakamura, Takashi, Mori, Takesada
Format: Article
Language:English
Subjects:
Administration, Oral
Adult
Aged
Aortic Aneurysm, Abdominal - drug therapy
Arteriosclerosis Obliterans - drug therapy
Atherosclerosis
Cholesterol - blood
Eicosapentaenoic Acid - pharmacology
Eicosapentaenoic Acid - therapeutic use
Female
Humans
Lipoprotein(a) - drug effects
Male
Middle Aged
Oral Administration
Statistics, Nonparametric
Thromboangiitis Obliterans - drug therapy
Total cholesterol
Triglyceride
Triglycerides - blood
Vascular Diseases - drug therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The effects of eicosapentaenoic acid (EPA) on serum lipoprotein (a) (Lp (a)) and other lipid levels in patients with vascular disease were examined. The serum levels of Lp (a), total cholesterol (TC), triglyceride (TG), low-density lipoprotein (LDL) and very-low-density lipoprotein (VLDL) were measured in 24 patients with vascular disease. An elevated serum Lp (a) level (39± 22 mg/dl) was noted in 9 patients, elevated total cholesterol level (263± 31 mg/dl) in 12 patients, elevated triglyceride level (240± 98 mg/di) in 10 patients and elevated LDL level (651±88 mg/dl) in 6 patients before administration of EPA. EPA (1, 800 mg/day) was given to these patients for long periods ranging from 6 to 24 months. The serum levels of Lp (a), TC, TG and LDL were lowered significantly (p< 0.05) after EPA administration for 12 and 18 months, for 6, 12, 18 and 24 months, for 18 months and for 12 and 18 months, respectively. These findings indicated that long-term administration of EPA may lower Lp (a) and serum lipids, which is beneficial for patients with various arterial diseases in terms of preventing progression of the disease. J Atheroscler Thromb, 1996 ; 2 : 107-109.
ISSN:1340-3478
1880-3873
DOI:10.5551/jat1994.2.107